Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis C differs in viral type 1 and 2 infections

Digestive Diseases and Sciences

Volumn 41, Issue 10, 1996, Pages 1925-1932

  Tsubota, Akihito ^a   Kumada, Hiromitsu ^b   Chayama, Kazuaki ^b   Arase, Yasuji ^b   Saitoh, Satoshi ^b   Koida, Isao ^b   Murashima, Naoya ^b   Suzuki, Yoshiyuki ^b   Kobayashi, Masahiro ^b   Takagi, Kimiko ^b   Kobayashi, Mariko ^b   Ikeda, Kenji ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NONE

Author keywords

Chronic hepatitis C virus infection; Hepatitis C viremia level; Hepatitis C virus type; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; LACTATE DEHYDROGENASE; LYMPHOBLAST INTERFERON; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VIREMIA; VIRUS TYPING;

CHRONIC DISEASE; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIREMIA;

EID: 10344262024     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02093591     Document Type: Article

References (25)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 321:1501-1506, 1989
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
3. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, Hosoda K, Tada M, Ohto M, Ito K, Okuda K: Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 36:1217-1222, 1991
4. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, Gross JB, Anderson ML, Parent K, Fleming CR, Cangemi JR, O'brien PC, Powis PE: Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Dig Dis Sci 38:601-607, 1993
5. Takada N, Takase S. Enomoto N, Takada A, Date T: Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14:35-40, 1992
6. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K, Iwasaki S, Kobayashi M, Kumada H: Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 8:535-539, 1993
7. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Detection of hepatitis C virus hy polymerase chain reaction and response to interferon therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293-299, 1992
8. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H: Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994
9. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T: Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 39:977-982, 1994
10. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877-883, 1993
11. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilher JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-1504, 1993
12. Urdea MS, Kolherg J, Warner BD, Horn T, Clyne J, Ku L, Running JA: A novel method for the detection of hepatitis B virus in human serum samples without blotting or radioactivity. In Luminescence Immunoassay and Molecular Applications. K Van Dyke, R Van Dyke (eds). Boca Raton, Florida, CRC Press, 1990, pp 275-291
13. Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, Mizokami M, Ohba K, Tanaka S, Hattori N, Nomoto A, Kohara M: Antigenicities of group I and II hepatitis C virus polypeptides - molecular basis of diagnosis. Virology 192:430-437, 1993
14. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M: Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347-1353, 1994
15. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981
16. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kohayashi M, Unakami M, Morinaga T, Kumada H: Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 13:1040-1043, 1991
17. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Sakai Y, Matsumoto T, Kohayashi M, Unakami M, Morinaga T, Kumada H: Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction. J Gastroenterol Hepatol 8:40-44, 1993
18. Kwok S, Higuchi R: Avoiding false positives with PCR. Nature 339:237-238, 1989
19. Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H: Genotypic suhtyping of hepatitis C virus. J Gastroenterol Hepatol 8:150-156, 1993
20. Simmonds P: Variability of hepatitis C virus. Hepatology 21:570-583, 1995
21. Lau JYN, Simmonds P, Urdea MS: Implications of variations of "conserved" regions of hepatitis C virus genome. Lancet 346:425-426, 1995
22. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115:700-704, 1991
23. 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 39:1273-1280, 1994
24. Kobayashi M, Kumada H, Arase Y, Chayama K, Tsubota A, Saito S, Koida I, Ikeda K, Hashimoto M, Iwasaki S, Kanda M, Takagi K, Nakano A: The HCV-bDNA probe method for measurement of HCV-RNA counts by HCV genotype. Int Hepatol Commun 2:213-217, 1994
25. Smith DB, Davidson F, Yap PL, Brown H, Kolberg J, Detmer J, Urdea M, Simmonds P, the International HCV Collaborative Study Group: Levels of hepatitis C virus in blood donors infected with different viral genotypes. J Infect Dis 173:727-730, 1996